Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Increased to $1,200.00 by Analysts at TD Cowen

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target lifted by equities researchers at TD Cowen from $1,030.00 to $1,200.00 in a report released on Tuesday, Benzinga reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. TD Cowen’s price objective points to a potential upside of 12.50% from the company’s previous close.

A number of other research firms also recently weighed in on REGN. Bank of America increased their target price on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the company an “underperform” rating in a research report on Friday, April 12th. Piper Sandler upped their target price on shares of Regeneron Pharmaceuticals from $1,000.00 to $1,166.00 and gave the stock an “overweight” rating in a report on Friday. Guggenheim boosted their price objective on Regeneron Pharmaceuticals from $1,040.00 to $1,180.00 and gave the stock a “buy” rating in a report on Thursday, July 18th. Canaccord Genuity Group reissued a “buy” rating and set a $1,152.00 price target on shares of Regeneron Pharmaceuticals in a research note on Thursday, June 27th. Finally, Evercore ISI assumed coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, May 14th. They set an “outperform” rating and a $1,150.00 price target for the company. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,074.95.

Regeneron Pharmaceuticals Trading Down 0.3 %

Shares of Regeneron Pharmaceuticals stock traded down $3.05 during trading on Tuesday, hitting $1,066.69. The company’s stock had a trading volume of 68,388 shares, compared to its average volume of 466,461. The stock has a market cap of $117.54 billion, a price-to-earnings ratio of 31.54, a price-to-earnings-growth ratio of 2.20 and a beta of 0.13. The stock has a 50-day moving average price of $1,026.92 and a two-hundred day moving average price of $973.34. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.27 and a quick ratio of 4.51. Regeneron Pharmaceuticals has a 52 week low of $721.51 and a 52 week high of $1,106.16.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $8.46 by ($0.49). Regeneron Pharmaceuticals had a return on equity of 16.83% and a net margin of 29.45%. The company had revenue of $3.15 billion for the quarter, compared to the consensus estimate of $3.19 billion. Equities research analysts anticipate that Regeneron Pharmaceuticals will post 37.12 EPS for the current fiscal year.

Insider Transactions at Regeneron Pharmaceuticals

In related news, Director Michael S. Brown sold 1,172 shares of Regeneron Pharmaceuticals stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $974.86, for a total value of $1,142,535.92. Following the sale, the director now owns 1,382 shares of the company’s stock, valued at approximately $1,347,256.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Regeneron Pharmaceuticals news, Director Michael S. Brown sold 1,172 shares of the stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $974.86, for a total transaction of $1,142,535.92. Following the completion of the transaction, the director now owns 1,382 shares of the company’s stock, valued at $1,347,256.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $1,059.24, for a total transaction of $105,924.00. Following the sale, the director now directly owns 17,882 shares of the company’s stock, valued at approximately $18,941,329.68. The disclosure for this sale can be found here. Insiders sold a total of 65,074 shares of company stock valued at $64,546,123 in the last three months. 7.48% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Hedge funds have recently modified their holdings of the company. West Paces Advisors Inc. boosted its stake in Regeneron Pharmaceuticals by 575.0% during the first quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 23 shares during the period. Crewe Advisors LLC acquired a new stake in Regeneron Pharmaceuticals during the 1st quarter worth approximately $28,000. Lynx Investment Advisory purchased a new position in Regeneron Pharmaceuticals in the 2nd quarter valued at approximately $33,000. MCF Advisors LLC grew its stake in shares of Regeneron Pharmaceuticals by 50.0% in the fourth quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 12 shares in the last quarter. Finally, BOK Financial Private Wealth Inc. purchased a new stake in shares of Regeneron Pharmaceuticals during the first quarter worth $37,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.